Precision BioSciences, Inc. - Common Stock - Çeyreklik Finansal İstatistikler (NASDAQ:DTIL)

Financials

İşletme faaliyetlerinden elde edilen nakit -18.68 M-19.05 M-20.27 M-15.27 M-11.25 M-11.94 M -58.73 M Yatırım faaliyetlerinden elde edilen nakit -97 K-314 K-12 K17 K-325 K-114 K -434 K Finansman faaliyetlerinden elde edilen nakit 5.92 M10.69 M5.3 M1.66 M77.52 M745 K 85.22 M Serbest nakit akışı -18.78 M-19.12 M-20.27 M-15.27 M-11.27 M-11.96 M -58.77 M

Precision BioSciences, Inc. - Common Stock

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences, Inc. - Common Stock

Haberler

Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial Results - Slideshow (NASDAQ:DTIL) 2026-05-27

Precision BioSciences hisseleri hepatit B denemesi verileriyle sıçradı

Precision BioSciences DMD gen terapisi preklinik verilerini sundu

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

Precision BioSciences DMD gen tedavisi denemesine kayıt açtı

AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Jones Trading, Precision BioSciences hissesi için alım önerisiyle kapsama başladı

Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Should You Buy Precision BioSciences (DTIL) After Golden Cross?

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18